Andere talen Ryvu Therapeutics S.A.

Aandelen

RVU

PLSELVT00013

Beurs gesloten - Warsaw S.E. Andere beurzen 17:55:46 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
54 ^PLN	-0,37%		-1,64%	-6,09%

17/05	Transcript : Ryvu Therapeutics S.A. - Special Call
13/03	Ryvu Therapeutics S.A. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Transcript : Ryvu Therapeutics S.A. - Special Call	17/05
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	06/03
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	14/02
Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml	31/01
Transcript : Ryvu Therapeutics S.A. - Special Call	11/12
Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023	07/12
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
Transcript : Ryvu Therapeutics S.A. - Special Call	23-10-23
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120	23-10-23
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13-09-23
Ryvu and TIM to enter Warsaw's mWIG40 index	31-08-23
Ryvu Therapeutics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	16-05-23
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	24-03-23
Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	11-12-22
BioNTech Forms Multi-Target Research Collaboration With Ryvu Therapeutics	30-11-22
BioNTech SE and Ryvu Therapeutics S.A. Enters into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates	30-11-22
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	23-11-22
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	03-11-22
Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium	26-10-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ryvu Therapeutics S.A.

Aandelen

RVU

PLSELVT00013

Andere talen

Filters